Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT02320968
Other study ID # 141619
Secondary ID
Status Terminated
Phase N/A
First received December 11, 2014
Last updated April 27, 2017
Start date December 2014
Est. completion date March 1, 2017

Study information

Verified date April 2017
Source Vanderbilt University Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is designed to determine if the addition of the MedclineTM Sleep Assist Device will decrease night-time gastroesophageal reflux disease events.


Description:

The MedcineTM Sleep Assist Device was recently developed by Amenity Health, Inc and is designed to elevate the head and torso and maintain a patient in the left-lateral position in order to decrease night-time/nocturnal acid reflux. The MedcineTM Sleep Assist Device is composed of a 9-inch incline base and a wrap-around body pillow. Traditionally wedge pillows have been recommended for patients with acid reflux. The addition of the body pillow helps to maintain the patient in the left-lateral position (LLP) during sleep, which has been shown to reduce night-time reflux compared to wedge alone, right lateral position and/or sleeping flat.

In healthy controls, sleeping in the left-lateral position with this device system significantly decreased esophageal acid exposure and overall episodes of acid reflux. To date, there has been no study in patients with extra-esophageal reflux (EER) and nocturnal heartburn.

Primary Objectives The primary objective of the this study is to evaluate the effect of a reflux pillow on esophageal acid exposure in patients complaining of nocturnal EER.

Secondary Objectives To evaluate the effect of the reflux pillow on nocturnal EER symptoms, sleep quality, daytime EER symptoms, and overall quality of life.


Recruitment information / eligibility

Status Terminated
Enrollment 10
Est. completion date March 1, 2017
Est. primary completion date March 1, 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- Male and female patients between the ages of 18 and 65;

- Between 5'4" and 6'2"

- Body Mass Index<32

- Willing and able to provide written informed consent;

- Understands the clinical study requirements and is able to comply with the follow-up schedule set forth in the protocol;

- Clinically diagnosed with gastroesophageal reflux disease with extra-esophageal symptoms (i.e. chronic cough, choking, aspiration, chronic post nasal drip, globus, sore throat, throat clearing);

- Presents with Reflux Symptom Index (RSI) > 13;

- Undergoing Esophagogastroduodenoscopy (EGD) as part of routine care;

- Undergoing 96-hour pH monitoring via BRAVO capsule as part of routine care.

Exclusion Criteria:

- Currently being treated with another investigational medical device and/or drug;

- Currently receiving treatment for sleep apnea with continuous positive airway pressure (CPAP);

- Female patients who are of child-bearing potential and not using an acceptable method of birth control, or is pregnant or breast-feeding;

- Suspected esophageal cancer;

- Confirmed nasopharyngeal cancer;

- Previously undergone Nissen Fundoplication;

- Hiatal hernia > 4 cm

Study Design


Related Conditions & MeSH terms


Intervention

Other:
MedclineTM Sleep Assist Pillow
The pillow is designed so that the sleeper can have proper upper-body elevation while sleeping on his or her left side without the need for placing blocks under the head of the bed and bothering anyone else who may be sleeping in the bed. The pillow supports the patient's head, back and body to provide comfort while reducing or relieving acid reflux symptoms during sleep.

Locations

Country Name City State
United States Vanderbilt University Medical Center, Endoscopy Lab, TVC 1410 Nashville Tennessee

Sponsors (2)

Lead Sponsor Collaborator
Vanderbilt University Medical Center Amenity Health, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of patients with reduced esophageal acid exposure during sleep The patient will use the sleep assist device from days 3 - 30 and will complete various questionnaires at weeks 2 and 4 to determine if night-time reflux symptoms were improved. 30 days
Secondary Number of patients with improved sleep quality The patient will use the sleep assist device from days 3 - 30 and will complete various questionnaires at weeks 2 and 4 to determine if sleep quality and overall quality of life was improved. 30 days
Secondary Number of patients with improved daytime extraesphageal reflux symptoms The patient will use the sleep assist device from days 3 - 30 and will complete various questionnaires at weeks 2 and 4 to determine if sleep quality and overall quality of life was improved. 30 days